Technical knowledge alone is not enough for pharmaceutical professionals
![](/46/pdcnewsitem/03/60/96/nonstop%20recruitment.png)
Pharmaceutical professionals must develop wider commercial and business skills if they want to continue to secure the top jobs, according to NonStop Recruitment.
The specialist pharmaceutical recruitment firm warned that as firms across the world are making significant cuts, professionals must go out of their way to develop wider skill sets or face falling behind their rivals in the job market. This follows on from reports that Merck has made over 36,000 professionals — around half of its workforce — redundant over the past 5 years and plans to reduce its headcount even further.
Abid Kanji, Associate Director at NonStop Recruitment commented: “The sector has faced numerous challenges over the past few years and some firms have, and continue to be, forced into making cuts in order to remain afloat. What this means for professionals is that they have to develop much wider skill sets to secure the top jobs, of which there are now far fewer. It’s not enough just to have the technical knowledge anymore — firms will expect that as a prerequisite — now they’re looking for that understanding combined with more developed commercial and general business skills.”
“This isn’t just limited to the pharmaceutical sector; it’s a trend that can be seen across the entire business arena. Organisations now want professionals who are much more rounded than in the past and are able to identify potential commercial opportunities even if this isn’t necessarily in their remit. The spread of M&A activity has also meant firms are interested in professionals with skills in managing external partnerships and regulatory affairs. Those who fail to build at least some of these qualities and only look to develop their direct market knowledge are likely to struggle when it comes to looking for a new role as they may find the market has left them behind.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance